What's Happening?
Tenpoint Therapeutics has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom for YUVEZZI™, an eye drop designed to treat presbyopia. This submission is part of
Tenpoint's global expansion strategy and follows the product's approval by the U.S. Food and Drug Administration (FDA) in January 2026. YUVEZZI™ is a dual-agent eye drop that has shown significant improvement in near vision in clinical trials, with no serious adverse events reported. The application is supported by data from two Phase 3 studies, BRIO I and BRIO II, which demonstrated the product's efficacy and safety over 12 months.
Why It's Important?
The submission of YUVEZZI™ for approval in the UK marks a significant step in addressing presbyopia, a condition affecting approximately 128 million people in the U.S. and 2 billion globally. The approval of this treatment in the UK could provide a new option for millions suffering from the gradual loss of close-up vision, typically beginning around age 45. The expansion into the UK market also represents a strategic move for Tenpoint Therapeutics to broaden its reach and impact in the global ophthalmic pharmaceutical industry. Successful approval could lead to increased market share and influence in the treatment of age-related vision conditions.
What's Next?
Following the submission, the MHRA will review the application under its International Recognition Procedure, which considers existing approvals from other regulatory bodies like the U.S. FDA. If approved, Tenpoint Therapeutics plans to continue its global expansion by submitting regulatory applications in other key regions. The company aims to collaborate with eye care professionals to bring innovative solutions to the aging population, potentially leading to further advancements in the treatment of presbyopia and other vision impairments.
